InvestorsHub Logo
Followers 66
Posts 1920
Boards Moderated 1
Alias Born 06/14/2001

Re: crazybetting post# 999

Monday, 09/21/2009 12:56:58 PM

Monday, September 21, 2009 12:56:58 PM

Post# of 1341
listen to the person that knows, or listen to the person with a pile of promo shares to sell to any last remaining suckers (I think you are the 2nd there)

as if u needed anything more - this is the ONLY piece of information you really needed to know its a scam...the rest is just gravy:

NEW YORK, NY, Sept. 16 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB - News) - GENova Biotherapeutics Inc. ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced it is in final negotiations with Beckpharma Ltd. ("Beckpharma") -a pharmaceutical development company also involved in cancer treatments for an extensive collaboration agreement.

The two companies are presently preparing the contractual details of their collaboration, with the mutual goal of bringing their respective drug patents to market as expeditiously as possible.

"Beckpharma's strength lies in identifying and acquiring promising cancer treatments through the relationships it has built with academic research institutions around the world," said Aaron Whiteman, CEO for GENova. "Their expertise and experience in that area would be a welcome enhancement to GENova's current sourcing efforts."

Both parties have also expressed interest in examining their current IP portfolios to gain insight into possible synergies between their drug targets, and the possibility of making a stronger, better, combined product by coordinating their biotechnologies and enable each company to save millions in R D cost.

Whiteman states that, "The ultimate goal of this collaboration deal is to determine how both companies can help each other to find new promising drug targets for acquisition, and to market our proprietary developmental drugs to Big Pharma such as Biogen, Elan, Merck's and Genentech for clinical studies and further development. The faster we usher our drug targets through the pipelines, the sooner we can start reaping financial rewards from our potential blockbuster drugs over entire length of the patents of 15 - 20 years."



sounds awful lot like the deal Beckpharma had with Nextgen (now an invisible pink)...

NextGen Bioscience, Inc. ("NextGen") (OTCBB: NXGB), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced its intention to collaborate
with Beckpharma Ltd. ("Beckpharma") - a pharmaceutical development company also involved in cancer treatments.

The two companies have formalised their desire to collaborate in a recent Letter of Intent, and are presently preparing the contractual details of
their collaboration. They plan to primarily focus on the sourcing of cancer treatments, but are open to future expansion to other therapeutic areas as well.

"Beckpharma's strength lies in identifying and acquiring promising cancer treatments through the relationships it has built with academic research
institutions around the world," said Konstantinos Kardiasmenos, CEO of NextGen.

"Their expertise and experience in that area would be a welcome enhancement to NextGen's current sourcing efforts."
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.